Current Practice Review in the Management of Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) presents as an acute inflammatory lung injury characterized by refractory hypoxemia and non-cardiac pulmonary edema. An estimated 10% of patients in the intensive care unit and 25% of those who are mechanically ventilated are diagnosed with ARDS. Increased awareness is warranted as mortality rates remain high and delays in diagnosing ARDS are common. The COVID-19 pandemic highlights the importance of understanding ARDS management. Treatment of ARDS can be challenging due to the complexity of the disease state and conflicting existing evidence. Therefore, it is imperative that pharmacists understand both pharmacologic and non-pharmacologic treatment strategies to optimize patient care. This narrative review provides a critical evaluation of current literature describing management practices for ARDS. A review of treatment modalities and supportive care strategies will be presented.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of pharmacy practice - 36(2023), 6 vom: 21. Dez., Seite 1454-1471 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chudow, Melissa B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute respiratory distress syndrome |
|---|
| Anmerkungen: |
Date Completed 08.11.2023 Date Revised 08.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/08971900221108713 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342492691 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342492691 | ||
| 003 | DE-627 | ||
| 005 | 20231226014236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/08971900221108713 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342492691 | ||
| 035 | |a (NLM)35728076 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chudow, Melissa B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Practice Review in the Management of Acute Respiratory Distress Syndrome |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2023 | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Acute respiratory distress syndrome (ARDS) presents as an acute inflammatory lung injury characterized by refractory hypoxemia and non-cardiac pulmonary edema. An estimated 10% of patients in the intensive care unit and 25% of those who are mechanically ventilated are diagnosed with ARDS. Increased awareness is warranted as mortality rates remain high and delays in diagnosing ARDS are common. The COVID-19 pandemic highlights the importance of understanding ARDS management. Treatment of ARDS can be challenging due to the complexity of the disease state and conflicting existing evidence. Therefore, it is imperative that pharmacists understand both pharmacologic and non-pharmacologic treatment strategies to optimize patient care. This narrative review provides a critical evaluation of current literature describing management practices for ARDS. A review of treatment modalities and supportive care strategies will be presented | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute respiratory distress syndrome | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a critical care | |
| 650 | 4 | |a neuromuscular-blocking agents | |
| 700 | 1 | |a Condeni, Melanie S |e verfasserin |4 aut | |
| 700 | 1 | |a Dhar, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Heavner, Mojdeh S |e verfasserin |4 aut | |
| 700 | 1 | |a Nei, Andrea M |e verfasserin |4 aut | |
| 700 | 1 | |a Bissell, Brittany D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmacy practice |d 1996 |g 36(2023), 6 vom: 21. Dez., Seite 1454-1471 |w (DE-627)NLM088682471 |x 1531-1937 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2023 |g number:6 |g day:21 |g month:12 |g pages:1454-1471 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/08971900221108713 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2023 |e 6 |b 21 |c 12 |h 1454-1471 | ||